Cumberland Pharmaceuticals (CPIX) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Nkarta (NKTX) over the past year, gaining 193.5% versus a loss of 36.9%. Over five years, CPIX leads with a +161.9% price change compared with -93.0% for NKTX. Cumberland Pharmaceuticals is the larger company by market cap ($87.6 million vs $81.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | NKTX |
|---|---|---|
| Share price | $5.84 | $1.14 |
| Market cap | $87.57M | $81.29M |
| 1-day change | -7.30% | +1.34% |
| YTD return | +46.73% | -38.65% |
| 1-year return | +193.47% | -36.94% |
| 5-year return | +161.88% | -93.05% |
| Forward P/E | 41.71 | — |
| EPS (TTM) | $-0.57 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | $0 |
| Revenue growth (YoY) | +17.57% | — |
| Net income (latest FY) | $-2.84M | $-104.08M |
| Gross margin | 85.02% | — |
| Operating margin | -6.27% | — |
| Net margin | -6.37% | — |
| 52-week high | $9.28 | $3.72 |
| 52-week low | $2.00 | $1.11 |
| Distance from 52-week high | -37.07% | -69.49% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +825.11% |
| Average volume | 114.52K | 1.02M |
| Shares outstanding | 15.00M | 71.62M |
| Employees | 88 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed NKTX by 230.4 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees
CPIX vs NKTX FAQ
Which is bigger, Cumberland Pharmaceuticals or Nkarta?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $87.57M compared with $81.29M for Nkarta (NKTX).
Which stock has performed better over the past year, CPIX or NKTX?
CPIX returned +193.47% over the past 12 months, compared with -36.94% for NKTX (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.